查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1781996

神經退化性疾病治療市場，按藥物類型、按疾病適應症、按給藥途徑、按配銷通路、按國家和地區 - 2025 年至 2032 年全球行業分析、市場規模、市場佔有率和預測

Neurodegenerative Disorder Therapeutics Market, By Drug Type, By Disease Indication, By Route of Administration, By Distribution Channel, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 311 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

報告重點

2024 年神經退化性疾病治療市場規模價值 172.439 億美元，2025 年至 2032 年的複合年成長率為 5.80%。

神經退化性疾病治療市場-市場動態

人口老化和標靶治療的進步推動市場成長

全球人口老化和標靶治療的突破正在重塑神經退化性疾病治療市場。根據世界衛生組織的數據，全球有超過 5,500 萬人患有失智症，預計到 2030 年這一數字將上升到 7,800 萬，到 2050 年將上升到 1.39 億。這種人口結構的變化凸顯了有效治療的迫切性。美國國立衛生研究院的 BRAIN 計畫等創新研究計畫已經開發出先進的基因遞送工具，可以精確靶向和激活特定大腦和脊髓細胞中的基因，為阿茲海默症和帕金森氏症等疾病帶來希望。同樣，歐洲神經退化性疾病研究聯合計劃 (JPND) 支持跨國項目，以加速治療進展。這些合作旨在透過創新治療方法和改善患者護理來減輕神經退化性疾病日益加重的負擔。

神經退化性疾病治療市場—關鍵見解

根據我們的研究分析師的分析，預計全球市場在預測期內（2025-2032 年）的年複合成長率約為 5.80%。

根據藥物類型細分，預計膽鹼酯酶抑制劑將在 2024 年佔據最大市場佔有率

根據疾病適應症細分，阿茲海默症是 2024 年最主要的疾病適應症

根據給藥途徑細分，口服給藥是 2024 年最主要的給藥途徑

按地區分類，北美是 2024 年的主要收入來源

神經退化性疾病治療市場-細分分析：

全球神經退化性疾病治療市場根據藥物類型、疾病適應症、給藥途徑、配銷通路和地區進行細分。

根據藥物類型，市場分為六類：N-甲基-D-天冬胺酸 (NMDA) 受體拮抗劑、多巴胺激動劑、單胺氧化酶-B (MAO-B) 抑制劑、膽鹼酯酶抑制劑、免疫調節劑和選擇性血清素再攝取抑制劑。膽鹼酯酶抑制劑透過增強認知功能，有助於阿茲海默症的治療。多巴胺激動劑和 MAO-B 抑制劑是控制帕金森氏症症狀的關鍵。 NMDA 受體拮抗劑有助於緩解記憶力減退，而選擇性血清素再攝取抑制劑 (SSRI) 和免疫調節劑則有助於緩解神經退化性疾病中的行為症狀和發炎。

根據疾病適應症，市場分為五類：阿茲海默症、帕金森氏症、亨廷頓氏症、肌萎縮性側索硬化症 (ALS) 和多發性硬化症 (MS)。由於全球高發病率和人口老化，阿茲海默症佔據主導地位。帕金森氏症的治療進展強勁，多巴胺標靶藥物療效顯著。 ALS 和亨丁頓舞蹈症的治療方案有限，仍然具有挑戰性。多發性硬化症受益於免疫療法的進步，可改善長期管理和患者生活品質。

神經退化性疾病治療市場—地理洞察

受醫療基礎設施、研究資金和人口老化等因素的影響，神經退化性疾病治療市場呈現顯著的地區差異。北美仍然處於領先地位，美國透過廣泛的臨床試驗、強大的製藥實力以及旨在解讀複雜腦部疾病的NIH BRAIN計劃等舉措做出了主要貢獻。歐洲緊隨其後，尤其是德國、法國和英國等國家，這些國家的政府支持計畫（如JPND（神經退化性疾病研究聯合計畫））支持跨國研究合作。以日本和中國為首的亞太地區由於老齡人口成長和醫療支出增加而經歷快速成長。尤其是日本，其失智症發病率位居世界前列，這促使其大力發展先進的治療方法。同時，拉丁美洲和中東地區正在透過提高意識、政府支持和國際合作逐步擴大其治療範圍，儘管基礎設施和可近性在這些地區仍然是發展挑戰。

神經退化性疾病治療市場-競爭格局：

神經退化性疾病治療市場的競爭格局由製藥巨頭和專注於創新療法的新興生物科技公司共同塑造。百健（Biogen）、羅氏（Roche）、禮來（Eli Lilly）和諾華（Novartis）等公司在開發針對阿茲海默症、帕金森氏症和肌萎縮性脊髓側索硬化症（ALS）等疾病的標靶生物製劑、基因療法和單株抗體方面處於領先地位。例如，儘管監管結果不一，百健在澱粉樣蛋白標靶療法方面的工作已引起全球關注。同時，規模較小的生物科技新創公司正在推動基於RNA的療法、幹細胞療法和神經保護劑的研發，這些研發通常得到與學術機構和政府機構合作的支持。為了克服神經退化性疾病藥物試驗的高失敗率，各公司之間建立了策略聯盟、許可協議和聯合研究計畫。公私合作夥伴關係（尤其是在美國和歐盟）正在培育創新管道，幫助在這個高風險、高需求的治療領域將早期發現與後期臨床成功聯繫起來。

最新動態：

2025年4月，處於臨床前階段的生物技術公司Transneural Therapeutics推出了創新神經塑性劑，旨在革新神經精神疾病的治療方法。這些新型化合物提供了一種比傳統迷幻藥更安全、更有效的替代品，標誌著下一代精神健康療法的突破。

2025年5月，賽諾菲宣布收購Vigil Neuroscience，將用於治療阿茲海默症的在研口服TREM2激動劑VG-3927納入其神經病學產品線。此舉強化了賽諾菲致力於開發創新神經退化性疾病療法的承諾。

2025年5月，ABLi Therapeutics公司成立，專注於開發由c-Abl激酶活化引起的神經退化性疾病的治療方法。其主要候選藥物Risvodetinib (ABLi-148009)是一種強效、可穿透腦的選擇性c-Abl激酶抑制劑，每日口服一次，旨在阻止或逆轉帕金森氏症的進展。

目錄

第1章：神經退化性疾病治療市場概述

  • 研究範圍
  • 市場估計年限

第2章：執行摘要

  • 市場片段
    • 神經退化性疾病治療市場（依藥物類型）
    • 神經退化性疾病治療市場片段（依疾病適應症）
    • 神經退化性疾病治療市場依給藥途徑分類
    • 神經退化性疾病治療市場片段（按配銷通路）
    • 神經退化性疾病治療市場（按國家/地區）
    • 神經退化性疾病治療市場（按地區）
  • 競爭洞察

第3章：神經退化性疾病治療的關鍵市場趨勢

  • 神經退化性疾病治療市場促進因素
    • 市場促進因素的影響分析
  • 神經退化性疾病治療市場限制
    • 市場限制的影響分析
  • 神經退化性疾病治療市場機遇
  • 神經退化性疾病治療市場未來趨勢

第4章：神經退化性疾病治療產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第5章：神經退化性疾病治療市場：地緣政治緊張局勢升級的影響

  • COVID-19 疫情的影響
  • 俄烏戰爭的影響
  • 中東衝突的影響

第6章：神經退化性疾病治療市場格局

  • 2024年神經退化性疾病治療市佔分析
  • 按主要製造商分類的細分數據
    • 成熟玩家分析
    • 新興企業分析

第7章：神經退化性疾病治療市場－依藥物類型

  • 概述
    • 按藥物類型分類的細分市場佔有率分析
    • N-甲基-D-天門冬胺酸（NMDA）受體拮抗劑
    • 多巴胺激動劑
    • 單胺氧化酶-B（MAO-B）抑制劑
    • 膽鹼酯酶抑制劑
    • 免疫調節劑
    • 選擇性血清素再攝取抑制劑

第 8 章：神經退化性疾病治療市場 - 依疾病適應症

  • 概述
    • 按疾病適應症分類的細分佔有率分析
    • 阿茲海默症
    • 帕金森氏症
    • 亨廷頓舞蹈症
    • 肌萎縮側索硬化症（ALS）
    • 多發性硬化症（MS）

第9章：神經退化性疾病治療市場－依給藥途徑

  • 概述
    • 按給藥途徑分類的細分市佔率分析
    • 口服
    • 注射劑
    • 透皮

第 10 章：神經退化性疾病治療市場 - 按配銷通路

  • 概述
    • 按配銷通路分類的細分市場佔有率分析
    • 醫院藥房
    • 零售藥局
    • 網路藥局

第 11 章：神經退化性疾病治療市場 - 按地域分類

  • 介紹
    • 按地區分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美神經退化性疾病治療主要製造商
    • 北美市場規模及預測（按國家/地區）
    • 北美市場規模及預測（依藥品類型）
    • 北美市場規模及預測（依疾病類型分類）
    • 北美市場規模及預測（按給藥途徑）
    • 北美市場規模及預測（按配銷通路）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲神經退化性疾病治療主要製造商
    • 歐洲市場規模及預測（按國家/地區）
    • 歐洲市場規模及預測（依藥品類型）
    • 歐洲市場規模及預測（依疾病類型分類）
    • 歐洲市場規模及預測（依管理途徑）
    • 歐洲市場規模及預測（按配銷通路）
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 瑞典
    • 俄羅斯
    • 波蘭
    • 歐洲其他地區
  • 亞太地區 (APAC)
    • 概述
    • 亞太地區神經退化性疾病治療主要製造商
    • 亞太地區市場規模及預測（依國家）
    • 亞太地區市場規模及預測（依藥品類型）
    • 亞太地區市場規模及預測（依疾病類型分類）
    • 亞太地區市場規模及預測（依管理途徑）
    • 亞太地區市場規模及預測（按配銷通路）
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲（LATAM）
    • 概述
    • 拉丁美洲神經退化性疾病治療主要製造商
    • 拉丁美洲市場規模及預測（按國家/地區）
    • 拉丁美洲市場規模及預測（按藥物類型）
    • 拉丁美洲市場規模及預測（依疾病類型分類）
    • 拉丁美洲市場規模及預測（依管理途徑）
    • 拉丁美洲市場規模及預測（按配銷通路）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲（MEA）
    • 概述
    • 中東和非洲神經退化性疾病治療主要製造商
    • MEA 市場規模及預測（依國家/地區）
    • MEA 市場規模及預測（依藥物類型）
    • MEA 市場規模及預測（依疾病類型分類）
    • MEA 市場規模及預測（依給藥途徑）
    • MEA 市場規模及預測（依配銷通路）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA 其餘地區

第 12 章：神經退化性疾病治療產業關鍵供應商分析

  • 競爭儀錶板
    • Competitive Benchmarking
    • Competitive Positioning
  • 公司簡介
    • AbbVie Inc.
    • ACADIA Pharmaceuticals Inc.
    • Alector Inc.
    • Allergan PLC
    • Amylyx Pharmaceuticals Inc.
    • Biogen Inc.
    • Boehringer Ingelheim International GmbH
    • Celgene Corporation
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd.
    • GlaxoSmithKline PLC
    • H. Lundbeck A/S
    • Merck Serono SA
    • Mitsubishi Tanabe Pharma Corporation
    • Novartis International AG
    • Orion Corporation
    • Pfizer Inc.
    • Sanofi SA
    • Teva Pharmaceutical Industries Ltd.
    • UCB SA
    • Others

第 13 章：360 度分析師視角

第 14 章：附錄

  • 研究方法
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
簡介目錄
Product Code: ANV5442

REPORT HIGHLIGHT

Neurodegenerative Disorder Therapeutics Market size was valued at US$ 17,243.90 Million in 2024, expanding at a CAGR of 5.80% from 2025 to 2032.

The Neurodegenerative Disorder Therapeutics Market encompasses treatments aimed at managing or slowing the progression of chronic neurological conditions such as Alzheimer's, Parkinson's, Huntington's disease, and amyotrophic lateral sclerosis (ALS). Rising life expectancy and aging populations worldwide are contributing to a growing patient base, with the World Health Organization estimating that over 55 million people currently live with dementia globally. Despite this, therapeutic development faces significant barriers, including high clinical trial failure rates and the complex nature of neurodegeneration. Limited understanding of disease mechanisms and the blood-brain barrier challenge effective drug delivery. However, the market is witnessing increased investment in gene therapy, monoclonal antibodies, and RNA-based treatments, offering hope for more targeted interventions. Initiatives by national health agencies, such as the U.S. NIH's BRAIN Initiative and Europe's Joint Programme on Neurodegenerative Disease Research (JPND), are creating collaborative frameworks that accelerate innovation and therapeutic advancements in this space.

Neurodegenerative Disorder Therapeutics Market- Market Dynamics

Aging Population and Advancements in Targeted Therapies to Propel Market Growth

The convergence of an aging global population and breakthroughs in targeted therapies is reshaping the neurodegenerative disorder therapeutics market. According to the World Health Organization, over 55 million people worldwide are living with dementia, a number projected to rise to 78 million by 2030 and 139 million by 2050. This demographic shift underscores the urgency for effective treatments. Innovative research initiatives, such as the U.S. National Institutes of Health's BRAIN Initiative, have developed advanced gene delivery tools that precisely target and activate genes in specific brain and spinal cord cells, offering hope for conditions like Alzheimer's and Parkinson's. Similarly, Europe's Joint Programme on Neurodegenerative Disease Research (JPND) supports transnational projects to accelerate therapeutic advancements. These collaborative efforts aim to address the growing burden of neurodegenerative diseases through innovative treatments and improved patient care.

Neurodegenerative Disorder Therapeutics Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 5.80% over the forecast period (2025-2032)

Based on Drug Type segmentation, Cholinesterase inhibitors were predicted to show maximum market share in the year 2024

Based on Disease Indication segmentation, Alzheimer's disease was the leading Disease Indication in 2024

Based on Route of Administration segmentation, Oral Administration was the leading Route of Administration in 2024

On the basis of region, North America was the leading revenue generator in 2024

Neurodegenerative Disorder Therapeutics Market- Segmentation Analysis:

The Global Neurodegenerative Disorder Therapeutics Market is segmented on the basis of Drug Type, Disease Indication, Route of Administration, Distribution Channel, and Region.

The market is divided into six categories based on Drug Type: N-methyl-D-aspartate (NMDA) Receptor Antagonists, Dopamine Agonists, Monoamine Oxidase-B (MAO-B) Inhibitors, Cholinesterase Inhibitors, Immunomodulators, and Selective Serotonin Reuptake Inhibitors. Cholinesterase inhibitors lead to Alzheimer's care by boosting cognitive function. Dopamine agonists and MAO-B inhibitors are key in managing Parkinson's symptoms. NMDA antagonists help moderate memory loss, while SSRIs and immunomodulators support behavioral symptoms and inflammation in neurodegenerative conditions.

The market is divided into five categories based on Disease Indication: Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Amyotrophic Lateral Sclerosis (ALS), and Multiple Sclerosis (MS). Alzheimer's disease dominates due to high global prevalence and aging demographics. Parkinson's sees strong therapeutic development with dopamine-targeting drugs. ALS and Huntington's remain challenging with limited options. Multiple Sclerosis benefits from immunotherapy advancements, improving long-term management and patient quality of life.

Neurodegenerative Disorder Therapeutics Market- Geographical Insights

The Neurodegenerative Disorder Therapeutics Market demonstrates significant regional variation, driven by healthcare infrastructure, research funding, and aging demographics. North America remains at the forefront, with the United States contributing majorly through extensive clinical trials, strong pharmaceutical presence, and initiatives like the NIH BRAIN Initiative aimed at decoding complex brain disorders. Europe follows closely, particularly in countries like Germany, France, and the UK, where government-backed programs such as JPND (Joint Programme on Neurodegenerative Disease Research) support cross-border research collaborations. The Asia-Pacific region, led by Japan and China, is experiencing rapid growth due to rising elderly populations and increased healthcare spending. Japan, in particular, faces one of the world's highest dementia rates, prompting advanced therapeutic development. Meanwhile, Latin America and the Middle East are gradually expanding their therapeutic reach through growing awareness, government support, and international partnerships, though infrastructure and accessibility remain developmental challenges in these regions.

Neurodegenerative Disorder Therapeutics Market- Competitive Landscape:

The competitive landscape of the Neurodegenerative Disorder Therapeutics Market is shaped by both pharmaceutical giants and emerging biotech firms focusing on novel treatment approaches. Companies like Biogen, Roche, Eli Lilly, and Novartis are leading efforts in the development of targeted biologics, gene therapies, and monoclonal antibodies for conditions such as Alzheimer's, Parkinson's, and ALS. Biogen's work on amyloid-targeting therapies, for instance, has sparked global attention despite mixed regulatory outcomes. Simultaneously, smaller biotech startups are advancing RNA-based treatments, stem cell therapies, and neuroprotective agents, often supported by collaborations with academic institutions and government bodies. Strategic alliances, licensing agreements, and joint research programs are common, as firms aim to overcome the high failure rates of neurodegenerative drug trials. Public-private partnerships, particularly in the U.S. and EU, are fostering innovation pipelines, helping bridge early-stage discoveries and late-stage clinical success in this high-risk, high-need therapeutic domain.

Recent Developments:

In April 2025, Transneural Therapeutics, a preclinical-stage biotech firm, introduced innovative neuroplastogens aimed at transforming treatment for neuropsychiatric disorders. These new compounds offer a safer, more effective alternative to traditional psychedelics, marking a breakthrough in next-generation mental health therapies.

In May 2025, Sanofi announced the acquisition of Vigil Neuroscience, adding VG-3927, an investigational oral TREM2 agonist for Alzheimer's disease, to its neurology pipeline. This move strengthens Sanofi's commitment to developing innovative neurodegenerative disorder therapeutics.

In May 2025, ABLi Therapeutics launched with a focus on developing treatments for neurodegenerative diseases arising from c-Abl kinase activation. Their lead candidate, Risvodetinib (ABLi-148009), is a potent, brain-penetrant, selective c-Abl kinase inhibitor designed for once-daily oral use, aiming to halt or reverse Parkinson's disease progression.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • AbbVie Inc.
  • ACADIA Pharmaceuticals Inc.
  • Alector Inc.
  • Allergan PLC
  • Amylyx Pharmaceuticals Inc.
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Celgene Corporation
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • H. Lundbeck A/S
  • Merck Serono S.A.
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis International AG
  • Orion Corporation
  • Pfizer Inc.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • UCB S.A.s
  • Others

GLOBAL NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019 - 2032

  • N-methyl-D-aspartate (NMDA) Receptor Antagonists
  • Dopamine Agonists
  • Monoamine Oxidase-B (MAO-B) Inhibitors
  • Cholinesterase Inhibitors
  • Immunomodulators
  • Selective Serotonin Reuptake Inhibitor

GLOBAL NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET, BY DISEASE INDICATION- MARKET ANALYSIS, 2019 - 2032

  • Alzheimer's Disease
  • Parkinson's Disease
  • Huntington's Disease
  • Amyotrophic Lateral Sclerosis (ALS)
  • Multiple Sclerosis (MS)

GLOBAL NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Oral
  • Injectable
  • Transdermal

GLOBAL NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

GLOBAL NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Neurodegenerative Disorder Therapeutics Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Neurodegenerative Disorder Therapeutics Market Snippet by Drug Type
    • 2.1.2. Neurodegenerative Disorder Therapeutics Market Snippet by Disease Indication
    • 2.1.3. Neurodegenerative Disorder Therapeutics Market Snippet by Route of Administration
    • 2.1.4. Neurodegenerative Disorder Therapeutics Market Snippet by Distribution Channel
    • 2.1.5. Neurodegenerative Disorder Therapeutics Market Snippet by Country
    • 2.1.6. Neurodegenerative Disorder Therapeutics Market Snippet by Region
  • 2.2. Competitive Insights

3. Neurodegenerative Disorder Therapeutics Key Market Trends

  • 3.1. Neurodegenerative Disorder Therapeutics Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Neurodegenerative Disorder Therapeutics Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Neurodegenerative Disorder Therapeutics Market Opportunities
  • 3.4. Neurodegenerative Disorder Therapeutics Market Future Trends

4. Neurodegenerative Disorder Therapeutics Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Neurodegenerative Disorder Therapeutics Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Neurodegenerative Disorder Therapeutics Market Landscape

  • 6.1. Neurodegenerative Disorder Therapeutics Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Neurodegenerative Disorder Therapeutics Market - By Drug Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Type, 2024 & 2032 (%)
    • 7.1.2. N-methyl-D-aspartate (NMDA) Receptor Antagonists
    • 7.1.3. Dopamine Agonists
    • 7.1.4. Monoamine Oxidase-B (MAO-B) Inhibitors
    • 7.1.5. Cholinesterase Inhibitors
    • 7.1.6. Immunomodulators
    • 7.1.7. Selective Serotonin Reuptake Inhibitor

8. Neurodegenerative Disorder Therapeutics Market - By Disease Indication

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Disease Indication, 2024 & 2032 (%)
    • 8.1.2. Alzheimer's Disease
    • 8.1.3. Parkinson's Disease
    • 8.1.4. Huntington's Disease
    • 8.1.5. Amyotrophic Lateral Sclerosis (ALS)
    • 8.1.6. Multiple Sclerosis (MS)

9. Neurodegenerative Disorder Therapeutics Market - By Route of Administration

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Route of Administration, 2024 & 2032 (%)
    • 9.1.2. Oral
    • 9.1.3. Injectable
    • 9.1.4. Transdermal

10. Neurodegenerative Disorder Therapeutics Market - By Distribution Channel

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Distribution Channel, 2024 & 2032 (%)
    • 10.1.2. Hospital Pharmacies
    • 10.1.3. Retail Pharmacies
    • 10.1.4. Online Pharmacies

11. Neurodegenerative Disorder Therapeutics Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Neurodegenerative Disorder Therapeutics Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Neurodegenerative Disorder Therapeutics Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.9. UK
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. UK Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.9.4. UK Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.3.9.5. UK Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.9.6. UK Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.10. France
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. France Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.10.4. France Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.3.10.5. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.10.6. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.11. Italy
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. Italy Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.11.4. Italy Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.3.11.5. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.11.6. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.12. Spain
      • 11.3.12.1. Overview
      • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.3. Spain Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Spain Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Spain Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.12.6. Spain Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.13. The Netherlands
      • 11.3.13.1. Overview
      • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.3. The Netherlands Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.13.4. The Netherlands Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.3.13.5. The Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.13.6. The Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Overview
      • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.14.6. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.15. Russia
      • 11.3.15.1. Overview
      • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.3. Russia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Russia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.15.6. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.16. Poland
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Poland Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Poland Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.17. Rest of Europe
      • 11.3.17.1. Overview
      • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.17.3. Rest of the Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.17.4. Rest of the Europe Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.3.17.5. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.17.6. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Neurodegenerative Disorder Therapeutics Key Manufacturers in Asia Pacific
    • 11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.4.5. APAC Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 11.4.6. APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.4.7. APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.8. China
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. China Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.8.4. China Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.4.8.5. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.8.6. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.9. India
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. India Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.9.4. India Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.4.9.5. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.9.6. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.13. Indonesia
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Indonesia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Indonesia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.14. Thailand
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Thailand Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Thailand Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.5. Latin America (LATAM)
    • 11.5.1. Overview
    • 11.5.2. Neurodegenerative Disorder Therapeutics Key Manufacturers in Latin America
    • 11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.5.5. LATAM Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 11.5.6. LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.5.7. LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa (MEA)
    • 11.6.1. Overview
    • 11.6.2. Neurodegenerative Disorder Therapeutics Key Manufacturers in Middle East and Africa
    • 11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.6.5. MEA Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 11.6.6. MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.6.7. MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Neurodegenerative Disorder Therapeutics Industry

  • 12.1. Competitive Dashboard
    • 12.1.1. Competitive Benchmarking
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. AbbVie Inc.
    • 12.2.2. ACADIA Pharmaceuticals Inc.
    • 12.2.3. Alector Inc.
    • 12.2.4. Allergan PLC
    • 12.2.5. Amylyx Pharmaceuticals Inc.
    • 12.2.6. Biogen Inc.
    • 12.2.7. Boehringer Ingelheim International GmbH
    • 12.2.8. Celgene Corporation
    • 12.2.9. Eli Lilly and Company
    • 12.2.10. F. Hoffmann-La Roche Ltd.
    • 12.2.11. GlaxoSmithKline PLC
    • 12.2.12. H. Lundbeck A/S
    • 12.2.13. Merck Serono S.A.
    • 12.2.14. Mitsubishi Tanabe Pharma Corporation
    • 12.2.15. Novartis International AG
    • 12.2.16. Orion Corporation
    • 12.2.17. Pfizer Inc.
    • 12.2.18. Sanofi S.A.
    • 12.2.19. Teva Pharmaceutical Industries Ltd.
    • 12.2.20. UCB S.A.
    • 12.2.21. Others

13. 360 Degree AnalystView

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us